These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26602737)

  • 1. [Bioequivalence of dermatological topical medicines:the Brazilian scenario and the challenges for health surveillance].
    Soares KC; Moraes MV; Gelfuso GM; Gratieri T
    Cien Saude Colet; 2015 Nov; 20(11):3599-608. PubMed ID: 26602737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update of the Brazilian Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products.
    Soares KC; Santos GM; Gelfuso GM; Gratieri T
    AAPS J; 2015 Nov; 17(6):1517-8. PubMed ID: 26122498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Requirements and Innovation: A Comparison of the Dermatologic Antifungal Drug Product Markets in Brazil and United States.
    Kollross B; Cunha-Filho M; Gelfuso GM; Gratieri T
    Ther Innov Regul Sci; 2019 Sep; 53(5):661-668. PubMed ID: 30286614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products.
    Braddy AC; Davit BM; Stier EM; Conner DP
    AAPS J; 2015 Jan; 17(1):121-33. PubMed ID: 25344440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic-driven framework for bioequivalence assessment of complex topical generic drug products.
    Lourenço D; Miranda M; Sousa JJ; Vitorino C
    Int J Pharm; 2024 Aug; 661():124398. PubMed ID: 38964491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in methodologies for evaluating bioequivalence of topical formulations.
    Shah VP
    Am J Clin Dermatol; 2001; 2(5):275-80. PubMed ID: 11721645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system.
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Generic drugs in Brazil: historical overview and legislation].
    Araújo LU; Albuquerque KT; Kato KC; Silveira GS; Maciel NR; Spósito PÁ; Barcellos NM; Souza Jd; Bueno M; Storpirtis S
    Rev Panam Salud Publica; 2010 Dec; 28(6):480-92. PubMed ID: 21308175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.
    Raney SG; Franz TJ; Lehman PA; Lionberger R; Chen ML
    Clin Pharmacokinet; 2015 Nov; 54(11):1095-106. PubMed ID: 26063051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers.
    Silva Mde F; Schramm SG; Kano EK; Mori Koono EE; Porta V; dos Reis Serra CH
    Clin Ther; 2010 Apr; 32(4):758-65. PubMed ID: 20435245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the advances and challenges in bioequivalence testing methods for complex topical generic products.
    Alomari N; Alhussaini W
    Front Pharmacol; 2024; 15():1330712. PubMed ID: 38389924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality and equivalence of topical products: A critical appraisal.
    Miranda M; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2020 May; 148():105082. PubMed ID: 31626969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.
    Freitas CG; Walsh M; Atallah ÁN
    BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of topical generic products. Part 1: Where are we now?
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Oct; 123():260-267. PubMed ID: 30053463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Brazilian Requirements for Therapeutic Equivalence of Orally Inhaled and Nasal Drug Products.
    Silva MC; Costa HS; Valadares BN; Grecchi L; Nagao L; Santos GML
    AAPS PharmSciTech; 2019 Jun; 20(6):235. PubMed ID: 31236849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human test models for bioequivalence of topical corticosteroids: a review.
    Olsen EA
    Int J Dermatol; 1992 Oct; 31 Suppl 1():9-13. PubMed ID: 1428469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
    Seoane-Vazquez E; Rodriguez-Monguio R; Hansen R
    Clin Drug Investig; 2016 Apr; 36(4):281-92. PubMed ID: 26818406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.